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Ionizing radiation (IR) exposure of cells in  vitro and in  vivo triggers a complex cellu-
lar response among which modifications of gene expression have been consistently 
reported. Nevertheless, little is currently known about the transcriptionally responsive 
genes which play a role in the inflammation response. In order to improve our understand-
ing of such transcriptional response to radiation in vivo, we simultaneously monitored the 
expression of 249 genes associated with the inflammation response over the course of 
the radiotherapy treatment in blood of patients treated for endometrial or head and neck 
cancer. We have identified genes whose transcriptional expression is either upregulated 
(ARG1, BCL2L1) or downregulated (MYC) several fold in vivo. These modifications were 
consistently detected across patients and further confirmed by quantitative real-time 
polymerase chain reaction (QRT-PCR); they were specifically significant toward the end 
of the radiotherapy treatment, 5 weeks following the first radiation fraction and more 
pronounced in endometrial patients (respectively, 2.9, 4.1, and 1.8 times). Importantly, 
in an attempt to correlate expression levels with normal tissue reaction to IR, we also 
identified three other genes CD40, OAS2, and CXCR1 whose expression level fluctu-
ations during radiotherapy were more pronounced in patients developing late normal 
tissue responses to curative radiotherapy after the end of the radiotherapy treatment. 
Overall, we identified inflammation-associated genes which are promising biomarkers of 
IR exposure and susceptibility to radiation-induced toxicity.
Keywords: radiation, inflammation, toxicity, biomarker, transcription
inTrODUcTiOn
Humans are exposed to ionizing radiation (IR) from both environmental and medical sources. 
At the cellular level, IR has cytotoxic effects and is a physiologically important stress inducing a large 
range of DNA lesions (1) to which cells respond by the activation of multiple signaling pathways. 
DNA damage triggers the DNA-damage response, a complex network that regulates cell cycle, pro-
liferation, and cell death. DNA repair is activated to ensure that the lesions are repaired efficiently 
and accurately with minimal impact on genome stability (2). Cellular exposure to IR also results 
TaBle 1 | list of endometrial and head and neck cancer patients and 
their prescribed dose, dose per fraction, and calculated volume of blood 
irradiated.
category Patient  
code
Prescribed 
dose  
(gy)
Dose per 
fraction  
(gy)
Mean-
irradiated 
blood volume 
(dm3)
Endometrial cancer 
patients
E1–E10 45 1.8 1.1
Head and neck cancer 
patients
N2 50 2 0.5
N1, N3 60 2
N8, N9 66 2
N4, N5, 
N7
70 2.1
2
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in complex alterations in gene expression (3, 4), a fundamental 
mechanism of great importance for cells in order to execute 
their functions. Many investigations on global gene expression 
profiling of IR-exposed whole blood samples have identified 
genes associated with the DNA-damage response. Among others, 
we found many genes activated by the transcription factor p53 
(encoded by the gene TP53) via the nuclear ataxia-telangiectasia 
mutated gene, the sensor of double-strand breaks (5–7), and 
some are promising biomarkers of radiation exposure for biologi-
cal dosimetry purposes, e.g., PCNA, DDB2, FDXR, CCNG1, and 
MDM2 (8–10).
Over recent years, a greater understanding has been obtained 
of the transcriptional response in cells and expression of specific 
genes can depend on radiation dose (11–13), dose rate (14, 15), 
radiation quality (16), and lapse between stress and analysis 
(17, 18). The level of dose also plays an important role. Low 
doses of IR induce genes in a linear dose-dependent manner 
(7) but specific immune responses were detected after low doses 
in whole blood, showing the involvement of both innate and 
adaptive immunity (19). Interestingly, the first mammalian 
radiation-induced protein-coding gene, i.e., tumor necrosis 
factor (TNF) was reported in the late 1980s (20). An increase 
in TNF-alpha (TNF-α) mRNA is accompanied by the increased 
production of TNF-α protein which is a mediator of the cel-
lular immune response. For example, TNF-α acts directly on 
vascular endothelium to increase the adhesion of leukocytes 
during the inflammatory process (21). In mammalian cells, IR 
elicits a multi-layered signaling response by activating many 
pro-survival pathways and key transcription factors (22). 
Among them, IR transiently activates the nuclear factor kappa 
B (NF-κB), a ubiquitous transcription factor that regulates gene 
expression profile of multiple genes. Importantly, NF-κB has a 
central role in immune and inflammatory responses because 
it regulates the expression of pro-inflammatory cytokines and 
chemokines such as TNF-α (23). Although the aforementioned 
gene is directly involved in the inflammation process and was 
one of the first genes to be reported as being transcriptionally 
activated by radiation, only a few publications specifically 
studied inflammation-associated transcription modifications 
in vitro (19, 24, 25).
Inflammation also plays a key role in the response to radiation 
in  vivo (26). As transcription factors regulate a wide spectrum 
of genes involved in inflammation, for example, NF-κB and 
p53 coregulate the induction of pro-inflammatory genes in 
primary human monocytes and macrophages (27), we decided 
to investigate IR exposure-associated transcriptional changes 
in an attempt to unravel the inflammation responses in vivo in 
human peripheral blood leukocyte (PBL) and platelets samples 
of patients undergoing radiotherapy treatment. Blood samples 
collected from endometrial and head and neck cancer patients 
treated by radiotherapy were analyzed at baseline and after the 
first, second, and last delivered dose (1.8 and 2 Gy, respectively). 
We investigated early and long-term chronic exposure effects on 
gene expression. Acute toxicity grading was evaluated as the worst 
grade of toxicity recorded during the treatment or up to 3 months 
after the end of treatment and late toxicity grading was evaluated as 
the worst grade of symptoms, persisting more than 3 months after 
the end of the treatment (see Materials and Methods for details). 
Moreover, we assessed interindividual variability in response 
among patients as some of them experienced toxic side effects 
of the radiotherapy treatment. Quantitative real-time polymerase 
chain reaction (QRT-PCR) was used to validate results obtained 
with the digital technology nCounter Analysis System, success-
fully used in the past to identify radiation-responsive genes in 
PBLs (28). Results for both techniques showed good correlation 
for all genes with R2 values ranging from 0.82 and 0.98.
MaTerials anD MeThODs
Patient radiotherapy Fractions and 
radiation Toxicity grading
Only cancer patients with no previous chemo- or radiotherapy 
were enrolled in the study. Patient ages ranged from 52 to 81 
of which 7 head and neck patients were male, 1 head and neck 
patient was female, and with the 10 endometrial patients being 
female. The areas of radiation exposure for each cancer treatment 
and the prescribed dose for each patient listed in Table 1. Blood 
samples from 10 endometrial cancer patients and 8 head and 
neck cancer patients were collected into PAXGene tubes before 
radiotherapy treatment and at different times post-exposure as 
shown in Table 2. Both patient subgroups were treated for the 
same tumor localization in order to prevent the variability usu-
ally observed among patients treated with radiotherapy and to 
allow the corresponding roles of the size of irradiation field and 
of the dose rate to be studied. Blood from endometrial and head 
and neck cancer patients was taken pre-exposure, 24 h after the 
1st fraction, 24 h after the 2nd fraction, and 24 h after the 25th 
fraction.
Side effects of treatment such as toxicity were also recorded 
for each patient (Table 2). Acute toxicity grading was evaluated 
as the worst grade of toxicity recorded during the treatment or up 
to 3 months after the end of the treatment—CTCAE v. 4.0 grading 
system was used as described in Table 3. The full definition of the 
grading system can be found at the RTOG website.1 Late toxicity 
grading was evaluated as the worst grade of symptoms, persist-
ing more than 3 months after the end of the treatment—RTOG/
EORTC late radiation toxicity scheme (29) was used.
1 https://www.rtog.org/ResearchAssociates/AdverseEventReporting.aspx.
TaBle 3 | list of cTcae v. 4.0 grading system used for acute toxicity 
grading and rTOg grading system used for late toxicity grading, 
including description of the grades in relevant locations.
Toxicity 
grade
cTcae v. 4.0 rTOg
Grade 1 Mild pain Intestine: mild diarrhea, cramping, bowel 
movements five times daily, slight rectal discharge, 
or bleeding
Subcutaneous/mucous membrane: slight induration, 
loss of subcutaneous fat, slight atrophy, and dryness
Grade 2 Moderate pain Subcutaneous/mucous membrane: moderate 
fibrosis and moderate atrophy
Grade 3 Severe pain Bone: severe pain, tenderness, complete arrest of 
bone growth, and dense bone sclerosis
Subcutaneous/mucous membrane: severe 
induration, loss of subcutaneous tissue, marked 
atrophy, and complete dryness
Grade 4 Life threatening Intestine: necrosis, perforation, and fistula
Grade 5 Death Death
TaBle 2 | list of cancer patients and their recorded acute and late toxicity grades according to rTOg/eOrTc late radiation morbidity criteria.
cancer patients Patient code Tumor 
grade
sample taken acute 
toxicity
late 
toxicity
late toxicity location
Endometrial cancer patients E1 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 1 Intestinal (diarrhea)
E2 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 1 None
E3 1 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 1 Intestinal (diarrhea)
E4 1 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 1 Intestinal (diarrhea)
E5 3 Pre-exposure, 24 h, 48 h, 5 weeks Grade 1 Grade 1 Intestinal (diarrhea)
E6 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 1 Intestinal (diarrhea)
E7 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 3 Grade 4 Intestinal (rectovaginal fistula)
E8 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 1 Intestinal (diarrhea)
E9 1 Pre-exposure, 24 h, 48 h, 5 weeks Grade 1 Grade 3 Bone (sacral plexopathy)
E10 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 None
Head and neck cancer patients N1 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 1 Grade 1 Subcutaneous/mucosal
N2 3 Pre-exposure, 24 h, 48 h, 5 weeks Grade 1 Early deatha
N3 3 Pre-exposure, 24 h, 48 h, 5 weeks Grade 1 Early deatha
N4 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 2 Subcutaneous/mucosal
N5 2 Pre-exposure, 24 h, 48 h, 5 weeks Grade 2 Grade 3 Subcutaneous/mucosal
N7 3 Pre-exposure, 24 h, 48 h Grade 2 Grade 2 Subcutaneous/mucosal
N8 2 Pre-exposure, 24 h, 48 h Grade 1 Grade 1 Subcutaneous/mucosal
N9 3 Pre-exposure, 24 h, 48 h Grade 1 Grade 1 Subcutaneous/mucosal
Patients with the highest toxicity grades (grades 3 and 4) are highlighted with a solid line.
aThe patients N2 and N3 died due to rapid progression of the cancer disease and not due to radiation toxicity (i.e., grade 5 or so-called “death directly related to radiation late effects”).
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Patient Blood sampling
Blood samples were collected from the radiotherapy-treated 
cancer patients in PAXGene tubes according to the manufactur-
ers’ protocol (Qiagen, PreAnalytiX GmbH, Hilden, Germany). 
The tubes were kept at RT for 2 h before being frozen at −20°C. 
RNA was extracted from the samples using the PAXGene Blood 
miRNA Kit (Qiagen, PreAnalytiX GmbH, Hilden, Germany) 
according to the manufacturers’ protocol. RNA quantity was 
assessed by Nanodrop ND2000 (Nanodrop, Wilmington, DE, 
USA), and RNA quality was assessed by Tapestation 2200 (Agilent 
Technologies, CA, USA).
ncounter analysis
Samples were analyzed by the nCounter Analysis System 
(NanoString Technologies®, Inc., Seattle, WA, USA) according 
to the manufacturers’ guidelines. The nCounter Analysis System 
utilizes a novel digital color-coded barcode technology that is 
based on direct multiplexed measurement of gene expression. 
The technology uses molecular “barcodes” and single-molecule 
imaging to detect and count hundreds of unique transcripts in 
a single reaction. The RNA sample was hybridized overnight in 
solution with the set of target-specific biotinylated capture probes 
and barcode containing reporter probes. The tubes were then 
covered and incubated at 65°C for 12–18 h in a thermocycler. The 
PrepStation collected hybridized probe/target complexes while 
washing away unhybridized probes. The washed complexes were 
then added to a cartridge containing a streptavidin-derivatized 
surface, which anchored the biotinylated capture probe end. The 
complexes were stretched and aligned by applying an electrical 
field to the immobilized complexes; the reporter (barcode)-
containing end was anchored during this process with a second 
biotin-containing oligonucleotide. To count the molecules, the 
cartridges containing the immobilized, aligned barcodes were 
placed in the Digital Analyzer. The nCounter Digital Analyzer 
counted individual fluorescent barcodes which are composed of 
seven spots made up of four colors specific for the gene of interest. 
It imaged each cartridge and using proprietary image analysis 
software, counted the individual barcodes across the surface. Data 
were collected in the form of a text file, containing a list of gene 
names and number of times the barcode for that gene is detected, 
providing a direct count of the number of transcripts. The raw 
code count data from the nCounter Analysis System were first 
normalized and background corrected using a standard curve 
4Manning et al. Radiotherapy-Associated Long-term Transcriptional Modifications
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constructed from spike-in controls. The molecular counts were 
normalized to internal controls and reference genes according 
to Geiss et al. (30). The samples were run using 90 ng RNA per 
sample on the Human Inflammation V2 panel, which consists of 
249 genes and scanned at 555 field of view (FOV). FOV is the area 
of the cartridge surface which is imaged by the Digital Analyzer 
with 555 FOV providing the most detailed scan. The raw code 
count data were first normalized and background corrected 
using a standard curve constructed from spike-in controls. The 
molecular counts were normalized to internal controls and refer-
ences genes according to Geiss et al. (30). Candidate genes that 
were selected were those that showed a significant upregulation 
in comparison to the control (t-test, p < 0.05).
Quantitative real-time Polymerase chain 
reaction
Reverse transcriptase reactions were performed using High 
Capacity cDNA Reverse transcription kit (Applied Biosystems, 
FosterCity, CA, USA) according to the manufacturer’s protocol 
with 350  ng of total RNA. QRT-PCR was performed using 
Rotor-Gene Q (Qiagen, Hilden, Germany). All reactions were 
run in triplicate using PerfeCTa® MultiPlex qPCR SuperMix 
(Quanta Biosciences, Inc., Gaithersburg, MD, USA) with primer 
and probe sets for target genes at 300  nM concentration each. 
3′6-Carboxyfluorescein (FAM) and CY5 (Eurogentec Ltd., 
Fawley, Hampshire, UK) were used as fluorochrome reporters 
for the double dye probes analyzed in multiplexed reactions with 
between two genes per run including the control. When validating 
primer and probes sets, the efficiencies were analyzed when the 
primer and probe sets were run separately and when ran together 
in a multiplex reaction to check for interference as per QMRT-
PCR guidelines (31). The primer sequences for QRT-PCR analysis 
were HPRT F: 5′ TCAGGCAGTATAATCCAAAGATGGT 3′, R: 
5′ AGTCTGGCTTATATCCAACACTTCG 3′, probe: 5′ CGCA 
AGCTTGCTGGTGAAAAGGACCC 3′; MYC F: 5′ CTTGTACC 
TGCAGGATCTGA 3′, R: 5′ GTCGAGGAGAGCAGAGAATC 
3′, probe 5′ CGCCCAAGTCCTGCGCCTCG 3′. Cycling param-
eters were 2 min at 95°C, then 45 cycles of 10 s at 95°C and 60 s at 
60°C. Data were collected and analyzed by Rotor-Gene Q Series 
Software. Gene target Ct (cycle threshold) values were normal-
ized to a hypoxanthine-guanine phosphoribosyltransferase 1 
(HPRT1) internal control. Ct values were converted to transcript 
quantity using standard curves obtained by serial dilution of 
PCR-amplified DNA fragments of each gene. The linear dynamic 
range of the standard curves covering six orders of magnitude 
(serial dilution from 3.2 × 10−4 to 8.2 × 10−10) gave PCR efficien-
cies between 93 and 103% for each gene with R2 > 0.998. Relative 
gene expression levels after irradiation were determined.
SYBRGreen PCR was performed using Rotor-Gene Q 
(Qiagen, Hilden, Germany). All reactions were run in triplicate 
using PerfeCTa SYBR® Green SuperMix (Quanta Biosciences, 
Inc., Gaithersburg, MD, USA) with primer sets for target genes 
at 500 nM concentration each. Cycling parameters were 2 min at 
95°C, then 40 cycles of 10 s at 95°C and 60 s at 60°C. Data were 
collected and analyzed by Rotor-Gene Q Series Software. Fold of 
change values were calculated using the delta–delta Ct method. 
The primer sequences for SYBRGreen analysis were HPRT F: 5′ 
TCAGGCAGTATAATCCAAAGATGGT 3′, R: 5′ AGTCTGG 
CTTATATCCAACACTTCG 3′; ARG1 F: 5′ CCACCTAAGTA 
AATGTGGAAAC 3′, R: 5′ ACCAAGAGGGAATTTGTAGAG 3′; 
BCL2L1 F: 5′ GGCTCTCTGCTGTACATATT 3′, R: 5′ GCAGCTC 
CTCACACATAA 3′; CD40 F: 5′ GCAGGAGACTGGCTAAATAA 
3′, R: 5′ CTGTGTACCCTTCCAGAAC 3′; OAS2 F: 5′ CTGG 
GTTCACAGATCTTTCT 3′, R: 5′ GTTCTTGACCTTTGGGTA 
TCT 3′; CXCR1 F: 5′ GTCTGCTGGAGACATTGAG 3′, R: 5′ 
GGGTTCTTGTGGCATAGAT 3′.
A primer-probe design and a SYBR green design were used 
in order to produce results quickly. A primer-probe design was 
used for the gene MYC as it was already available in our lab. SYBR 
green was used for the other new genes identified by nCounter to 
provide confirmation of the results.
statistical analysis
Statistical analysis of the biological data was performed using 
Minitab and Stata. Data points represent the mean  ±  SEM. 
p Values  ≤  0.05 were considered statistically significant. The 
data were tested for normal distribution. Parametric (t-test) and 
non-parametric (Mann–Whitney, Kruskal–Wallis) tests were 
used to test nCounter results for significance of candidate genes. 
Kruskal–Wallis tests were performed to test for significance of 
SYBR green QPCR results. p-Trend tests were performed using 
the software Stata to test for significance of dose-to-gene associa-
tions of BCL2L1 and OAS2.
resUlTs
ncounter analysis
Blood from endometrial and head and neck cancer patients was 
taken pre-exposure, 24 h after the 1st fraction, 24 h after the 2nd 
fraction, and 24 h after the 25th fraction. Using the nCounter, 
we analyzed the transcriptional expression level of 249 genes 
associated with the inflammation process. Candidate genes 
were selected that showed a significant upregulation in com-
parison to the control (p < 0.05). From the inflammation panel, 
comparing blood samples obtained before and after the first or 
second fraction, we did not identify genes whose expression was 
consistently and significantly modified by radiation exposure 
(data not shown). To the contrary, a significant modification 
of expression after radiation exposure was detected at the last 
time point. Importantly, three genes were identified from the 
nCounter analysis that showed a modification in expression at 
day 35 (5 weeks following the first fraction, 24 h following the 
last fraction) as shown in Figures 1A,C,E (endometrial cancer 
patients) and Figures 2A,C,E (head and neck cancer patients). 
Two genes, ARG1 and BCL2L1 were upregulated while MYC was 
downregulated. These results were then confirmed by QRT-PCR 
analysis.
Quantitative Pcr analysis
We monitored previously validated radiation-responsive genes to 
confirm that IR exposure could be detected in PBL. The majority 
of genes investigated responded rapidly to radiation exposure, 
nCounter QRT-PCR
*
A
C
E
B
*
D
*
F
FigUre 1 | The box plot shows the fold change in expression of the genes ARG1 (a,B), BCL2L1 (c,D), and MYC (e,F) in endometrial cancer patients 
24 h after the 1st fraction, 24 h after the 2nd fraction, and 24 h after the 25th fraction. The box plot is composed of a rectangular box representing the 
middle 50% of the data, the median value indicated by the horizontal line inside the box, lines representing the upper and lower 25% of the distribution, and outliers 
indicated by asterisks. Expression was measured using the nCounter (left) and QRT-PCR (right) analysis. Fold changes in expression compared to non-irradiated 
blood (and relative to HPRT gene). Significance was calculated using the Kruskal–Wallis test where *p < 0.05.
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reaching a peak of expression between 24 h after the first frac-
tion (day 1) and 24 h after the second fraction (day 2) (data not 
shown). Mean gene expression values of nCounter plotted against 
QRT-PCR data showed good agreement between both methods 
with R2 values ranging from 0.90 to 0.99 for endometrial samples 
and ranging from 0.5 to 0.97 for head and neck samples for genes 
showing a change in expression (data not shown). The gene ARG1 
was upregulated at 5  weeks after fractionated therapy in 9 out 
of the 10 endometrial cancer patients (fold of change ranging 
from 0.7 for patient E4 up to 4.5-fold increase in expression for 
patient E6) (Figure 1B). This increase was also evident in head 
and neck cancer patients, but to a lower extent with fold changes 
of 3.3 and 1.8 in patients N1 and N2 with the rest showing no 
increase in expression at 5 weeks (Figure 2B). The gene BCL2L1 
showed a large variation in expression among endometrial 
cancer patients at 5 weeks with an 11.8-fold increase for patient 
E2 while other patients showed no modification of expression 
(Figure 1D). The expression of BCL2L1 in head and neck cancer 
patients was low reaching 1.5-fold increase at week 5 for patient 
N4 but the remaining patients showing no increase in expression 
(Figure 2D). To the contrary, the gene MYC was consistently and 
gradually downregulated in both endometrial (Figure  1F) and 
head and neck cancer patients (Figure  2F) from the first time 
point (1 day post-first fraction) to the last one (5 weeks) where the 
downregulation became significant for the endometrial patients. 
At this late time point, MYC was downregulated 1.8-fold on aver-
age in endometrial cancer patient samples and showed a 1.5-fold 
downregulation in head and neck cancer patients. As with the 
other genes, this response was stronger in the endometrial cancer 
patients.
Toxicity analysis
Out of the 10 endometrial cancer patients, 1 of them, patient 
E7, recorded the highest level of acute (grade 3) and late toxicity 
nCounter QRT-PCR
A
C
E
B
D
F
FigUre 2 | The box plot shows the fold change in expression of the genes ARG1 (a,B), BCL2L1 (c,D), and MYC (e,F) in head and neck cancer 
patients 24 h after the 1st fraction, 24 h after the 2nd fraction, and 24 h after the 25th fraction. The box plot is composed of a rectangular box representing 
the middle 50% of the data, the median value indicated by the horizontal line inside the box, lines representing the upper and lower 25% of the distribution, and 
outliers indicated by asterisks. Expression was measured using the nCounter (left) and RT-PCR (right) analysis. Fold changes in expression compared to non-
irradiated blood (and relative to HPRT gene).
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of grade 4 (Table  2) diagnosed as a rectovaginal fistula. Late 
stage toxicity was also identified in patient E9 who had pain-
ful sacral plexopathy. In the head and neck cancer patients, 
the highest toxicity level of grade 3 was recorded in patient 
N5 who experienced severe induration. We retrospectively 
searched for inflammation-associated genes whose expression 
would have been modified specifically in these three patients. 
Although we could not single out any gene with a specific up- or 
downregulation for patient E7, who had the highest late toxicity 
grade, the nCounter analysis identified two genes, CD40 and 
OAS2, following the same pattern of expression with a slight 
increased expression of 1.3- and 1.4-fold in the endometrial 
cancer patient E9 at 48  h (Figures  3A,C). By the end of the 
radiotherapy treatment, the expression levels were inverted and 
a clear downregulation of sixfold and eightfold could be seen. 
This was confirmed by QRT-PCR analysis (Figures 3B,D). We 
then analyzed the data for patient N5. Of importance, the pat-
tern of expression was different from patient E9, the nCounter 
analysis also identified OAS2 as well as another gene CXCR1, 
showing an increased expression in the head and neck cancer 
patient N5 at 5 weeks (Figures 4A,C). This was confirmed by 
QRT-PCR analysis which showed an increase of 3- and 4.8-fold 
in expression at 5  weeks for OAS2 and CXCR1, respectively 
(Figures 4B,D).
Head and neck cancer patients received treatments with 
50–70  Gy. Dose versus fold change in gene expression per 
day was examined for patients receiving the different treat-
ments. A slight dose–response with large variability was seen 
in only two of the genes (BCL2L1, OAS2) at 5  weeks (data 
not shown). A p-trend test was performed for these genes 
nCounter QRT-PCR
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FigUre 3 | Fold change in expression of the genes CD40 (a,B) and OAS2 (c,D) in endometrial cancer patients 24 h after the 1st fraction, 24 h after 
the 2nd fraction, and 24 h after the 25th fraction. Expression was measured using the nCounter (left) and RT-PCR (right) analysis. Fold changes in expression 
compared to non-irradiated blood (and relative to HPRT gene).
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and although a trend was viable from the graphs, it was not 
statistically significant with a p value of 0.398 for OAS2 and 
a p value of 0.257 for BCL2L1. The toxicity grading was ana-
lyzed by categorizing the gene expression response at the 25th 
fraction into two categories (grades 1 +  2 and grades 3 +  4). 
The grading of all patients could only be combined for the 
gene OAS2 due to the fact that different genes were identified 
for the two sets of cancer patients. For the gene OAS2 at the 
25th fraction, a Mann–Whitney test was performed giving a 
p value of 0.475. Such analysis combining all types of late 
toxicities does not incorporate information on the localization 
of the toxicity which for patient E9 was in the bone while it 
was intestinal in E7 and mucosal in N5. Therefore, it may be 
more relevant to look at patients on a case by case basis where 
further details, such as location of toxicity, provide important 
information for transcriptional analysis. When the data were 
combined into two categories at the 25th fraction for the gene 
CD40 for endometrial cancer patients, this only resulted in six 
samples for the grade 1 category and two samples for the grade 
3 and grade 4 categories. A Mann–Whitney test was performed 
giving a p value of 0.867. When the data were combined into 
two categories at the 25th fraction for the gene CXCR1 for head 
and neck patients, this again only resulted in two samples for the 
grade 1 and grade 2 categories and one sample for the grade 3 
category. Unfortunately such analyses have limited significance 
with the small samples size (i.e., only one sample in the grade 3 
category), and a p value could not be obtained. Due to the small 
samples sizes and lack of statistical analysis, these graphs were 
not included in the manuscript.
DiscUssiOn
radiation-induced inflammatory 
Biomarkers
Biological research has been providing characterization and 
understanding of the complex actions of IR on biological processes. 
IR causes multiple types of damage to DNA but also the formation 
of reactive oxygen species which induce stress responses, inflam-
mation, and release of cytokines, growth factors, and chemokines 
(32, 33). Immunological biomarkers of radiation-induced fibro- 
sis and pneumonitis in cancer radiotherapy patients were 
reviewed by Sprung et  al. (34). Nonetheless, radiation-induced 
inflammation-associated transcripts expressed in circulating PBL 
in vivo have not yet been explored. In particular, long-term effects 
have rarely been investigated and only the effects of acute long-
term exposure on global gene expression patterns in irradiated 
human lymphocytes were reported (35). In this study, we looked 
specifically at transcripts of genes associated with inflammation 
and induced by IR and their correlation with long-term effects 
(i.e., after 3 months after the end of RT) such as radiation toxicity.
The use of the recently developed nCounter technology 
enabled us to screen 249 genes associated with inflammation 
simultaneously (Human Inflammatory V2 panel). We previously 
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FigUre 4 | Fold change in expression of the genes OAS2 (a,B) and CXCR1 (c,D) in head and neck patients 24 h after the 1st fraction, 24 h after the 
2nd fraction, and 24 h after the 25th fraction. Expression was measured using the nCounter (left) and RT-PCR (right) analysis. Fold changes in expression 
compared to non-irradiated blood (and relative to HPRT gene).
8
Manning et al. Radiotherapy-Associated Long-term Transcriptional Modifications
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 412
scan the expression of hundreds of genes following IR exposure 
using this technique successfully (28). Three genes were identified 
as radiation-induced inflammatory biomarkers in PBL in  vivo. 
ARG1 and BCL2L1 show increased expression mainly toward the 
end (35  days) of the radiotherapy treatment while MYC shows 
a gradual increased downregulation with cumulative doses 
of radiotherapy treatment. For all three genes, this response 
was more pronounced in endometrial cancer patients where it 
becomes significant. Although we cannot provide an explanation, 
it is possible that this is a dose effect as the irradiated volume of 
body mass as well as circulating blood is higher in endometrial 
cancer patients in comparison to head and neck patients 
(see Table  1). The first gene, ARG1, catalyzes the hydrolysis of 
arginine to ornithine and urea and is expressed in macrophages. 
Interestingly its expression has been found upregulated in vitro, 
in primary monocytes-derived macrophages obtained from blood 
samples collected from patients before and after the first delivered 
2 Gy radiotherapy dose in breast cancer patients (36). The authors 
found that the level of ARG1 mRNA significantly correlated with 
higher grades of radiation-induced acute skin toxicities in early 
breast cancer patients. As discussed later, we also looked at acute 
and late radiation toxicity but could not find any correlation as 
the increase in ARG1 expression was found in three patients on 
day 1 and in nine patients at 5 weeks where the level of expres-
sion becomes significantly different from basal expression. In our 
in vivo study, ARG1 can be rather considered as a late biomarker 
of radiation exposure than a biomarker of radiation toxicity. The 
second gene we found to be significantly upregulated at 35 days, 
BCL2L1, is a member of the BCL-2 protein family, which are 
involved in a number of cellular functions such as apoptosis and 
regulation of the outer mitochondrial membrane channel (VDAC) 
opening. BCL2L1 expression after radiotherapy has previously 
been investigated in prostate cancer patients undergoing external 
beam radiotherapy and found to be upregulated with increasing 
fatigue (37). Here, the expression of BCL2L1 increases with time 
and at week 5 the gene is upregulated in nine patients; however, 
fatigue was not measured and so no comparisons to this factor can 
be made. BCL2L1 has also been investigated as a predictive marker 
of radioresistance, however, there are conflicting reports. BCL2L 
expression in head and neck patients has shown to be associated 
with a favorable outcome in a study involving 400 patients (38) 
while another study associates BCL2L1 expression with tumor 
recurrence (39). Finally, MYC is a well-known transcription factor 
that plays a central role in cancer development processes including 
cell proliferation, growth, and apoptosis. MYC has been previously 
upregulated in cases of radiation-induced angiosarcoma (40, 41) 
and glioblastoma, with its expression associated with longer overall 
survival (42) but here we see a strong and consistent downregula-
tion in all endometrial cancer patients after radiotherapy.
We chose to analyze whole blood transcriptional responses 
as it was a simple and reliable protocol to collect and preserve 
RNA using specifically designed PAXgene tubes. PBL represents 
a complex combination of different cell types (neutrophils, 
lymphocytes, eosinophils, and basophils), allowing the study of 
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a collective tissue response with neutrophils the most abundant 
(~60%) and short lived; therefore, a late change in transcription 
(i.e., 5 weeks) is unlikely to be from this specific subpopulation. 
On the other hand, it is not possible in this study to confirm that 
these radiation-induced modulations of expression are global or 
potentially cell-type specific. It is probable that results could be 
refined by sorting PBL subpopulations which may have a stronger 
transcriptional response to radiation. For instance, it has been 
shown that several biological responses in cluster of differentia-
tion CD4+ cells could be more sensitive to low doses of radiation 
than CD56+ and CD8+ (43). When blood volumes are sufficient, 
further studies should be designed to isolate blood subpopula-
tions before performing cell-type specific transcription analyses.
We and others have shown that gene expression analysis could 
be a powerful tool to predict radiation exposure for biological 
dosimetry purposes and such inflammatory gene expression 
signature (i.e., ARG1, BCL2L1, and MYC) may be useful not only 
for biodosimetric triage, as well as to monitor the progress of 
treatment and recovery.
radiation-induced Toxicity Biomarkers
Normal tissue reactions to radiotherapy vary in severity among 
patients and cannot be accurately predicted, limiting treatment 
doses (44). The existence of heritable radiosensitivity syndromes 
[e.g., Ref. (45, 46)] suggests that normal tissue reaction severity 
is determined, at least in part, by genetic factors and these may 
be revealed by differences in gene expression. Transcriptional 
responses in lymphoblastoid cells can be used to understand 
the genetic basis for variation in human radiosensitivity (47), 
to assess interindividual susceptibility to DNA damaging agents 
for the prediction of therapeutic response to drugs (48), and to 
predict clinical outcome in human cancers (49). For example, we 
have previously shown that cyclin-dependent kinase inhibitor 1A 
(CDKN1A) transcriptional response associates with abnormal 
acute sensitivity to radiation treatment (50). Transcriptional res- 
ponses to radiation (51, 52) also reported that changes of expres-
sion in a specific set of genes after in vitro irradiation of stimulated 
peripheral lymphocytes can, to some extent, successfully predict 
severe late reaction status.
Inflammation has a protective role and is a response mecha-
nism involving multiple immune cells. Nevertheless, chronic 
inflammation is also associated with the development of chronic 
diseases such as radiation toxicity. In this study, we also searched 
for differences in gene expression discriminating individuals with 
marked responses with the aim to identify potential biomarkers 
of radiation toxicity that would facilitate normal tissue response 
prediction.
Three genes, CD40, OAS2, and CXCR1, were identified as 
potential biomarkers of normal tissue toxicity in cancer patients 
after radiotherapy. In endometrial cancer patients, we observed 
by simple visual screening that the expression of CD40 and OAS2 
was particularly variable in patient E9 at the different time points 
studied although the number of patients studied here didn’t 
allow us to conclude in terms of statistical significance. CD40 is 
a member of the TNF-receptor superfamily, which is involved 
in mediating a number of inflammatory processes with interfer-
ence of the CD40–CD40 ligand. Interestingly, earlier work also 
reported a reduction of expression in radiation-induced lung 
toxicity in mice (53). The second gene, OAS2, is a member of the 
2–5A synthetase family which is involved in the immune response 
to viral infections. Expression of OAS2 has been suggested as a 
biomarker for disease and it has been reportedly upregulated in 
psoriasis and squamous cell carcinoma patients (54) and in mice 
in response to cigarette smoke and influenza virus (55).
Expression of OAS2 was particularly inconstant in endome-
trial patient E9 and head and neck patient N5, both with reported 
toxicity side effects. In the endometrial cancer patients, expres-
sion of OAS2 was upregulated at 48  h in patient E9, who was 
recorded as having the second highest late toxicity score of grade 
3. This increase was followed by a drop of expression of a factor 
of 12 at 5 weeks, possibly indicating the beginning of an inflam-
mation response and the painful sacral plexopathy the patient 
experienced. This upregulation was not seen in patient E7 who 
recorded the highest toxicity level of grade 4. Although we do 
not have an explanation for this, it might be due to the specificity 
of the response to the type of toxicity (patient E7 was diagnosed 
with rectovaginal fistula).
The expression of OAS2 was also upregulated in the head and 
neck cancer patient N5, which reported the highest level of toxic-
ity, grade 3. This upregulation was weak at day 2 but amplified 
after 5 weeks. We speculate that the later upregulation compared 
to patient E9 is possibly due to the smaller area treated for head 
and neck cancer patients and thus a threshold level of radiation 
exposure possibly needs to be achieved in order to upregulate 
this gene. More likely, the difference at 35 days, i.e., upregulation 
(N5) and downregulation (E9) might be linked to the nature of 
the tissue irradiated. Nevertheless, a shift in expression might be 
an indication of radiation toxicity occurring later.
Possibly, the clearest difference in expression between patients 
was for the gene CXCR1. It is a member of the G-protein-coupled 
receptor family, binding with high affinity to IL8 and mediating 
chemotaxis. With such a central role in the inflammatory response, 
CXCR1 has been targeted for the development of pain-relieving 
drugs (56, 57). Similar to the gene OAS2, CXCR1 was clearly 
upregulated in patient N5 at the 5-week time point with an increase 
in expression of nearly fivefold, again indicating that the inflamma-
tory response in this patient can be detected by these genes.
As a general comment, we acknowledge that the tumors for 
which the patients were treated by radiotherapy may affect the 
basal level of expression of many inflammation genes analyzed 
in PBL in this study (58). Despite the fact that it might have 
affected the sensitivity of detection, it should not have affected the 
specificity, as the patient blood samples obtained 24 h before the 
beginning of the treatment were used to set-up the background 
level of expression of these genes. Potential confounding factors 
such as age at treatment and gender (for head and neck cancer 
patients) could not be investigated in this study due to the small 
sample size but would be of importance in future studies.
summary and conclusion
To summarize, this study allowed the identification of three 
inflammatory-associated genes (ARG1, BCL2L1, and MYC) 
whose expression is consistently modified in cancer patients 
by the radiotherapy treatment more than a month after the 
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beginning of the treatment and, although these results require 
confirmation and extension, it suggests the possibility of predict-
ing the severity of radiation toxicity by monitoring the leukocyte 
mRNA levels of specific genes (for example, CD40, OAS2, and 
CXCR1). Identification of such biomarkers could improve treat-
ment, comfort for the patient, and reduce side effects. These 
genes may possibly be used to identify patients who are at risk 
of developing severe toxicity and appropriate measures could be 
taken to reduce radiation toxicity in these patients. We have iden-
tified potential biomarkers of late toxicity in which expression 
was upregulated only after completion of radiotherapy, but before 
clinical signs could be detected. The changes in gene expression 
24 h after the last radiotherapy fraction (25th) precede the late 
tissue reaction developed in patients E7 and N5. Upregulation of 
these biomarkers would not influence the indication or dose of 
radiation since it can be detected after the end of the treatment. 
However, more intensive surveillance and supportive care may 
be needed in patients with detected activity of these biomarkers 
after the treatment. Our findings are important for future radia-
tion late morbidity understanding and may be a potential aim for 
targeting in late morbidity prevention.
In conclusion, this study demonstrates the importance of 
further exploration of the modifications of transcription in res-
ponse to IR exposure in genes associated with an inflammation 
response and the immune system. In general, it has the potential 
to be a source of biomarkers allowing to complete the portfolio of 
identified mRNA transcripts for monitoring radiation exposure 
during radiotherapy on one hand and, perhaps more importantly, 
of radiation toxicity on the other one.
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